Maddalena Rossi

Maddalena Rossi

Auto-generated profile, based on publicly available information

Maddalena Rossi

Center for Diagnosis and Treatment of Cardiomyopathies

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GGGiulia Gagno
Giulia Gagno
FFFederico Ferro
Federico Ferro
AFAlessandra Lucia Fluca
Alessandra Lucia Fluca
MJMilijana Janjusevic
Milijana Janjusevic
MRMaddalena Rossi
Maddalena Rossi
Aneta AleksovaAneta Aleksova
Aneta Aleksova
Ischemic heart disease (IHD) is among the leading causes of death in developed countries. Its pathological origin is traced back to coronary atherosclerosis, a lipid-driven immuno-inflammatory disease of the arteries that leads to multifocal plaque development. The primary clinical manifestation of IHD is acute myocardial infarction (AMI),) whose prognosis is ameliorated with optimal timing of revascularization. Paradoxically, myocardium re-perfusion can be detrimental because of ischemia-reperfusion injury (IRI), an oxidative-driven process that damages other organs. Amyloid-β (Aβ) plays a physiological role in the central nervous system (CNS). Alterations in its synthesis, concentration and clearance have been connected to several pathologies, such as Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA). Aβ has been suggested to play a role in the pathogenesis of IHD and cerebral IRI. The purpose of this review is to summarize what is known about the pathological role of Aβ in the CNS; starting from this evidence, we will illustrate the role played by Aβ in the development of coronary atherosclerosis and its possible implications in the pathophysiology of IHD and myocardial IRI. Better elucidation of Aβ’s contribution to the molecular pathways underlying IHD and IRI could be of great help in developing new therapeutic strategies.

30 June 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MRMaddalena Rossi
Maddalena Rossi
GVGuerino Giuseppe Varrà
Guerino Giuseppe Varrà
APAldostefano Porcari
Aldostefano Porcari
Riccardo SaroRiccardo Saro
Riccardo Saro
LPLinda Pagura
Linda Pagura
MMMarco Merlo
Marco Merlo
The epidemiology of cardiac amyloidosis (CA), traditionally considered a rare and incurable disease, has changed drastically over the last ten years, particularly due to the advances in diagnostic methods and therapeutic options in the field of transthyretin CA (ATTR-CA). On the one hand, the possibility of employing cardiac scintigraphy with bone tracers to diagnose ATTR-CA without a biopsy has unveiled the real prevalence of the disease; on the other, the emergence of effective treatments, such as tafamidis, has rendered an early and accurate diagnosis critical. Interestingly, the following subgroups of patients have been found to have a higher prevalence of CA: elderly subjects > 75 years, patients with cardiac hypertrophy hospitalized for heart failure with preserved ejection fraction, subjects operated on for bilateral carpal tunnel syndrome, patients with cardiac hypertrophy not explained by concomitant factors and individuals with aortic valve stenosis. Many studies investigating the prevalence of CA in these particular populations have contributed to rewriting the epidemiology of the disease, increasing the awareness of the medical community for a previously underappreciated condition. In this review, we summarized the latest evidence on the epidemiology of CA according to the different clinical settings typically associated with the disease.

13 September 2021 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Open access
PDF file
MRMaddalena Rossi
Maddalena Rossi
EFEnrico Fabris
Enrico Fabris
DBDavide Barbisan
Davide Barbisan
LMLaura Massa
Laura Massa
GSGianfranco Sinagra
Gianfranco Sinagra
Increased levels of low-density lipoprotein cholesterol (LDL-C) are recognized as a primary risk factor for atherosclerotic cardiovascular disease, which remains the leading cause of death worldwide. Lowering LDL-C levels clearly reduces the risk of cardiovascular events, with benefits related to both absolute reduction and duration of treatment; however, a threshold below which low LDL-C levels can be dangerous has never been established. Since the discovery of statins, cardiovascular research has focused on developing new lipid-lowering agents. Ezetimibe and proprotein convertase subtilisin–kexin type 9 inhibitors have been found to further reduce LDL-C values and subsequent cardiovascular risk. Novel recently approved inclisiran and bempedoic acid, currently being tested in cardiovascular outcomes studies, are further expanding our pharmacological armamentarium, enabling the clinician to diminish residual risk related to LDL-C. Moreover, new agents are paving the way to successful treatment of homozygous familial hypercholesterolemia. This review summarizes the main characteristics of current and emerging lipid-lowering therapies to assist with comprehensive evidence-based decision making.

Verified
Journal Article
Open access
PDF file
Aneta AleksovaAneta Aleksova
Aneta Aleksova
FFFederico Ferro
Federico Ferro
GGGiulia Gagno
Giulia Gagno
LPLaura Padoan
Laura Padoan
Riccardo SaroRiccardo Saro
Riccardo Saro
GSGianfranco Sinagra
Gianfranco Sinagra
Survivors after a myocardial infarction (MI), especially those with diabetes mellitus (DM), remain at high risk of further events. Identifying and treating factors that may influence survival may open new therapeutic strategies. We assessed the impact on prognosis of DM and hypovitaminosis D (hypovitD), alone or combined. In this prospective, observational study, 1081 patients were enrolled surviving an MI and divided into four groups according to their diabetic and VitD status. The primary end-point was composite of all-cause mortality, angina/MI and heart failure (HF). Secondary outcomes were mortality, HF and angina/MI. During a follow-up of 26.1 months (IQR 6.6–64.5), 391 subjects experienced the primary end-point. Patients with DM or hypovitD had similar rate of the composite end-point. Patients with only hypovitD or DM did not differ regarding components of composite end-point (angina p = 0.97, HF p = 0.29, mortality p = 0.62). DM and VitD deficiency had similarly adjusted risks for primary end-point (HR 1.3, 95%CI 1.05–1.61; HR 1.3, 95% CI 1.04–1.64). The adjusted HR for primary composite end-point for patients with hypovitD and DM was 1.69 (95%CI 1.25–2.29, p = 0.001) in comparison to patients with neither hypoD nor DM. In conclusion, DM and hypovitD, individually and synergistically, are associated with a worse outcome after MI.

21 April 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
RWRobin Willixhofer
Robin Willixhofer
Massimo MapelliMassimo Mapelli
Massimo Mapelli
NBNikita Baracchini
Nikita Baracchini
NCNicola Campana
Nicola Campana
TCTeresa Maria Capovilla
Teresa Maria Capovilla
PAPiergiuseppe Agostoni
Piergiuseppe Agostoni
Background: The RoMa classification, based on peak heart rate and oxygen pulse derived from cardiopulmonary exercise testing, was recently proposed to stratify patients with hypertrophic cardiomyopathy by physiological reserve during exercise. We aimed to externally validate RoMa in an independent multicenter cohort with hypertrophic cardiomyopathy and assess its association with long‐term clinical outcomes. Methods: In this retrospective multicenter cohort study patients with hypertrophic cardiomyopathy, undergoing cardiopulmonary exercise testing, were consecutively enrolled. Patients were enrolled regardless of left ventricular outflow tract obstruction and were naïve to disease‐specific therapy (eg, mavacamten). Patients were categorized into RoMa I to IV based on percentage of predicted heart rate and oxygen pulse. The primary end point was a composite of all‐cause and cardiovascular death, sudden cardiac death, or aborted sudden cardiac death, heart failure–related hospitalization, stroke, systemic embolism, surgical myectomy, and heart transplantation. Results: The study included 292 patients (age 51 [36–63] years, 70% male sex, 30% with obstructive left ventricular outflow tract). Functional capacity declined hierarchically across RoMa groups (peak oxygen uptake 29.2 to 17.9 mL/kg/min; P ‐trend <0.001). During follow‐up (≈6 years), 68 composite events occurred. Kaplan–Meier analysis showed significant differences in event‐free survival across groups (log‐rank P =0.019). In multivariable analysis, RoMa II to IV compared with RoMa I were independently associated with higher hazard ratios (HRs) for the composite outcome (HRs, 3.89–5.37; all P <0.05), whereas genotype, LVEF <50%, male sex, and left ventricular outflow tract obstruction were not predictive. Conclusions: The RoMa classification independently predicts long‐term, clinically relevant outcomes in hypertrophic cardiomyopathy regardless of left ventricular outflow tract obstruction and may provide a novel approach to risk stratification.

21 November 2023 in Cardiologia Ambulatoriale – Outpatient Cardiology
Verified
Journal Article
Open access
GSGianfranco Sinagra
Gianfranco Sinagra
MRMaddalena Rossi
Maddalena Rossi
CICarla Indennidate
Carla Indennidate
MCMarco Cittar
Marco Cittar
MMMarco Masè
Marco Masè
MMMarco Merlo
Marco Merlo